Study of Cardiovascular Health Outcomes in the Era of Claims Data

Circulation

Volumn 133, Issue 2, 2016, Pages 156-164

  Psaty, Bruce M ^a,b,c,d   Delaney, Joseph A ^b   Arnold, Alice M ^b   Curtis, Lesley H ^e   Fitzpatrick, Annette L ^b   Heckbert, Susan R ^b,d   McKnight, Barbara ^b   Ives, DIane ^f   Gottdiener, John S ^g   Kuller, Lewis H ^f   Longstreth, W T ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Department of Epidemiology ^*  (United States)

^c U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

epidemiology; heart failure; incidence; myocardial infarction; stroke

Indexed keywords

GLUCOSE BLOOD LEVEL; LIPID;

ANALYSIS; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH INSURANCE; HEALTH SURVEY; HOSPITALIZATION; HUMAN; INSURANCE; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MEDICARE; MULTICENTER STUDY; PUBLIC HOSPITAL; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HEALTH SURVEYS; HOSPITALIZATION; HOSPITALS, VETERANS; HUMANS; INSURANCE CLAIM REVIEW; INTERNATIONAL CLASSIFICATION OF DISEASES; LIPIDS; MALE; MANAGED CARE PROGRAMS; MEDICARE; RISK FACTORS; SAMPLING STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84956657644     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.018610     Document Type: Article

References (45)

1. Blumenthal D, Davis K, Guterman S. Medicare at 50: origins and evolution. N Engl J Med. 2015;372:479-486. doi: 10.1056/NEJMhpr1411701.
2. Polgreen LA, Suneja M, Tang F, Carter BL, Polgreen PM. Increasing trend in admissions for malignant hypertension and hypertensive encephalopathy in the United States. Hypertension. 2015;65:1002-1007. doi: 10.1161/HYPERTENSIONAHA.115.05241.
3. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362:2155-2165. doi: 10.1056/NEJMoa0908610.
4. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, GoulDing MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157-164. doi: 10.1161/CIRCULATIONAHA.114.012061.
5. Cutrona SL, Toh S, Iyer A, Foy S, Cavagnaro E, Forrow S, Racoosin JA, Goldberg R, Gurwitz JH. Design for validation of acute myocardial infarction cases in Mini-Sentinel. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):274-281. doi: 10.1002/pds.2314.
6. Saczynski JS, Andrade SE, Harrold LR, Tjia J, Cutrona SL, Dodd KS, Goldberg RJ, Gurwitz JH. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):129-140. doi: 10.1002/pds.2313.
7. Andrade SE, Harrold LR, Tjia J, Cutrona SL, Saczynski JS, Dodd KS, Goldberg RJ, Gurwitz JH. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):100-128. doi: 10.1002/pds.2312.
8. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411-418. doi: 10.1001/jama.2010.920.
9. Go AS, Singer D, Cheetham TC, Toh D, Reichman M, Graham D, Southworth MR, Zhang R, Houstoun M, Wu YT, Mott K, Gagne J. Mini-Sentinel Medical Product Assessment: a protocol for assessment of dabigatran. Posted for public comment December 30, 2013. http://mini-sentinel.org/assessments/medical- events/details.aspx?ID=219. Accessed December 10, 2015.
10. Graham DJ, Zhou EH, McKean S, Levenson M, Calia K, Gelperin K, Ding X, MaCurdy TE, Worrall C, Kelman JA. Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockers. Pharmacoepidemiol Drug Saf. 2014;23:331-339. doi: 10.1002/pds.3548.
11. Hlatky MA, Ray RM, Burwen DR, Margolis KL, Johnson KC, Kucharska-Newton A, Manson JE, Robinson JG, Safford MM, Allison M, Assimes TL, Barvy AA, Berger J, Cooper-DeHoff RM, Heckbert SR, Li W, Liu S, Martin LW, Perez MV, Tindle HA, Winkelmayer WC, Stefanick ML. Use of Medicare data to identify coronary heart disease outcomes in the Women's Health Initiative. Circ Cardiovasc Qual Outcomes. 2014;7:157-162.
12. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, Cruise RG, Theroux S. Surveillance and ascertainment of cardiovascular events: the Cardiovascular Health Study. Ann Epidemiol. 1995;5:278-285.
13. Rosamond WD, Chambless LE, Sorlie PD, Bell EM, Weitzman S, Smith JC, Folsom AR. Trends in the sensitivity, positive predictive value, falsepositive rate, and comparability ratio of hospital discharge diagnosis codes for acute myocardial infarction in four US communities, 1987-2000. Am J Epidemiol. 2004;160:1137-1146. doi: 10.1093/aje/.
14. Jones SA, Gottesman RF, Shahar E, Wruck L, Rosamond WD. Validity of hospital discharge diagnosis codes for stroke: the Atherosclerosis Risk in Communities Study. Stroke. 2014;45:3219-3225. doi: 10.1161/STROKEAHA.114.006316.
15. Heckbert SR, Kooperberg C, Safford MM, Psaty BM, Hsia J, McTiernan A, Gaziano JM, Frishman WH, Curb JD. Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol. 2004;160:1152-1158. doi: 10.1093/aje/.
16. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263-276.
17. Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study: the Cardiovascular Health Study Collaborative Research Group. J Clin Epidemiol. 1992;45:683-692.
18. Psaty BM, Kuller LH, Bild D, Burke GL, Kittner SJ, Mittelmark M, Price TR, Rautaharju PM, Robbins J. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol. 1995;5:270-277.
19. Price TR, Psaty B, O'Leary D, Burke G, Gardin J. Assessment of cerebrovascular disease in the Cardiovascular Health Study. Ann Epidemiol. 1993;3:504-507.
20. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35:1628-1637.
21. Longstreth WT Jr, Bernick C, Fitzpatrick A, Cushman M, Knepper L, Lima J, Furberg CD. Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. Neurology. 2001;56:368-375.
22. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR. Coagulation factors, inflammation markers, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Med. 2002;113:636-642.
23. Robbins JA, Biggs ML, Cauley J. Adjusted mortality after hip fracture: from the Cardiovascular Health Study. J Am Geriatr Soc. 2006;54:1885-1891. doi: 10.1111/j.1532-5415.2006.00985.x.
24. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, Newman A, Loehr L, Folsom AR, Elkind MS, Lyles MF, Kronmal RA, Yende S. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313:264-274. doi: 10.1001/jama.2014.18229.
25. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med. 2000;19:1141-1164.
26. Parikh NI, Gona P, Larson MG, Fox CS, Benjamin EJ, Murabito JM, O'Donnell CJ, Vasan RS, Levy D. Long-term trends in myocardial infarction incidence and case fatality in the National Heart, Lung, and Blood Institute's Framingham Heart study. Circulation. 2009;119:1203-1210. doi: 10.1161/CIRCULATIONAHA.108.825364.
27. Yasaitis LC, Berkman LF, Chandra A. Comparison of self-reported and Medicare claims-identified acute myocardial infarction. Circulation. 2015;131:1477-1485. doi: 10.1161/CIRCULATIONAHA.114.013829.
28. Schellenbaum GD, Heckbert SR, Smith NL, Rea TD, Lumley T, Kitzman DW, Roger VL, Taylor HA, Psaty BM. Congestive heart failure incidence and prognosis: case identification using central adjudication versus hospital discharge diagnoses. Ann Epidemiol. 2006:16:15-122.
29. Re III VL, Kaynes K, Goldberg D, Forde KA, Carbonari DM, Fortier K, Hennessy S, Reddy KR, Pawloski PA, Daniel GW, Cheetham TC, Iyer A, Coughlin KO, Toh D, Boudreau D, Cooper WO, Selvam N, Selvan MS, VanWormer JJ, Avigan M, Houstoun M, Zornberg GL, Racoosin JA, Shoaibi A. Validity of codes to identify cases of severe acute liver injury in the Mini-Sentinel Distributed Database. December 6, 2012. http://www. mini-sentinel.org/methods/outcome-validation/details.aspx?ID=103. Accessed December 10, 2015.
30. Floyd JS, Heckbert SR, Weiss NS, Carrell DS, Psaty BM. Use of administrative data to estimate the incidence of statin-related rhabdomyolysis. JAMA. 2012;307:1580-1582. doi: 10.1001/jama.2012.489.
31. Greenland S. Variance estimation for epidemiologic effect estimates under misclassification. Stat Med. 1988;7:745-757.
32. Lash TL, Schmidt M, Jensen AØ, Engebjerg MC. Methods to apply probabilistic bias analysis to summary estimates of association. Pharmacoepidemiol Drug Saf. 2010;19:638-644. doi: 10.1002/pds.1938.
33. Fox MP, Lash TL, Greenland S. A method to automate probabilistic sensitivity analyses of misclassified binary variables. Int J Epidemiol. 2005;34:1370-1376. doi: 10.1093/ije/dyi184.
34. Setiawan VW, Virnig BA, Porcel J, Henderson BE, Le Marchand L, Wilkens LR, Monroe KR. Linking data from the Multiethnic Cohort Study to Medicare data: linkage results and application to chronic disease research. Am J Epidemiol. 2015;181:917-919. doi: 10.1093/aje/kwv055.
35. Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, Hennessy S, Nelson JC, Racoosin JA, Robb M, Schneeweiss S, Toh S, Weiner MG. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):1-8. doi: 10.1002/pds.2343.
36. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340:14-22. doi: 10.1056/NEJM199901073400103.
37. deFilippi CR, Christenson RH, Kop WJ, Gottdiener JS, Zhan M, Seliger SL. Left ventricular ejection fraction assessment in older adults: an adjunct to natriuretic peptide testing to identify risk of new-onset heart failure and cardiovascular death? J Am Coll Cardiol. 2011;58:1497-1506. doi: 10.1016/j.jacc.2011.06.042.
38. Bernick C, Kuller L, Dulberg C, Longstreth WT Jr, Manolio T, Beauchamp N, Price T; Cardiovascular Health Study Collaborative Research Group. Silent MRI infarcts and the risk of future stroke: the Cardiovascular Health Study. Neurology. 2001;57:1222-1229.
39. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49-S73. doi: 10.1161/01.cir.0000437741.48606.98.
40. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a.
41. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382:1762-1765. doi: 10.1016/S0140-6736(13)62388-0.
42. Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study. JAMA Intern Med. 2014;174:1964-1971. doi: 10.1001/jamainternmed.2014.5336.
43. Muntner P, Colantonio LD, Cushman M, Goff DC Jr, Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA. 2014;311:1406-1415. doi: 10.1001/jama.2014.2630.
44. Psaty BM, Prentice RL. Variation in event rates in trials of patients with type 2 diabetes. JAMA. 2009;302:1698-1700. doi: 10.1001/jama.2009.1497.
45. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131:34-42. doi: 10.1161/CIRCULATIONAHA.114.013255.